Chinese biopharma known for toripalimab, a PD-1 immuno-oncology antibody approved in China and the US.
Chinese biopharma known for toripalimab, a PD-1 immuno-oncology antibody approved in China and the US.
Earns from toripalimab sold in China, where national insurance reimbursement widens access at lower prices, and from licence income: Coherus sells it in the US as Loqtorzi and makes upfront and milestone payments to Junshi under a 2021 agreement.
In one line: A Chinese Bristol Myers Squibb-style oncology immunotherapy developer.
Moat: narrow (IP / patents, regulatory licence). First Chinese-developed PD-1 approved by FDA; patent-protected antibody.
Headquarters: Shanghai, China · Founded: 2012 · Employees: 2,903
Size Shanghai Junshi Biosciences (1877.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $3.49B, the 306th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$13.92 on 18 Nov 2026.
Performance Over six months the shares fell 38.4%, against +8.1% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue grew 35.8% over the last twelve months (peer median +7.9%); the operating margin is -14.3% (peer median 12.2%).
Valuation It trades at 8.4× enterprise value to sales against a peer median of 3.1× (4th most expensive of 16).
Capital Return on invested capital runs 10.7 points below its cost of capital (8.6% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$3.65B | HK$2.70B | HK$2.11B | HK$1.66B | HK$1.69B |
| Revenue growth | — | +28% | +27% | -2% | — |
| Gross profit | HK$3.12B | HK$1.96B | HK$1.42B | HK$789M | HK$835M |
| EBITDA | n/a | -HK$667M | -HK$1.09B | -HK$2.41B | -HK$2.85B |
| Net income | -HK$480M | -HK$949M | -HK$1.39B | -HK$2.52B | -HK$2.78B |
| Free cash flow | -HK$848M | -HK$1.35B | -HK$2.25B | -HK$3.02B | -HK$2.46B |
| Capital expenditure | HK$901M | HK$833M | HK$749M | HK$920M | HK$458M |
| Total debt | HK$7.98B | HK$4.61B | HK$3.12B | HK$1.97B | HK$1.48B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Shanghai Junshi Biosciences 1877.HK | $3.49B | -38% | +36% | -14% | 8.4× | n/a |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 7.3× | 11.6% |
| Akeso 9926.HK | $7.01B | -48% | +42% | -25% | 12.9× | n/a |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 3.1× | -13.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1877.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.0% | +4.5% | lowest of 21 |
| 6-month return | -38.4% | +8.1% | lowest of 20 |
| Distance from 52-week high | -54.8% | -18.8% | lowest of 21 |
| Revenue growth (TTM) | +35.8% | +7.9% | 5th highest of 18 |
| Operating margin | -14.3% | 12.2% | 2nd lowest of 16 |
| EV / Sales | 8.4× | 3.1× | 4th most expensive of 16 |
| ROIC minus cost of capital | -10.7 pp | +4.3 pp | 5th lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $3.49B | -38% | +36% | -14% | 8.4× | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 6.6× | 49.2% | +367.3% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 20.4× | n/a | n/a |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 3.1× | -2.1% | +12.0% |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 2.8× | n/a | n/a |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | 9.3× | 58.0% | +4.2% |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | 106.6× | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 2.6× | -3.4% | +10.6% |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 3.8× | n/a | n/a |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 0.6× | -4.9% | +7.8% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 3.2× | 6.4% | +5.9% |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 2.5× | 4.7% | +4.5% |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 1.8× | -4.1% | -1.0% |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.73B | -9% | -10% | 19% | 2.3× | -7.0% | +2.0% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | 5.2× | 34.7% | +159.5% |
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 0.3× | -10.0% | +5.4% |